MedTrace Logo

IRAPe, Irisin and IL-34 in Patients With Type 2 Diabetes

NCT04107259 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-07-29

No results posted yet for this study

Summary

Aim: This study aimed to evaluate the role of extracellular part of insulin regulated aminopeptidase (IRAPe), IL-34, Irisin, and Visfatin in the development of insulin resistance in patients with type 2 diabetes mellitus.

Methods: parallel study enrolled 60 non-diabetic control subjects and 60 newly-diagnosed type 2 diabetics, matched for age, body mass index and sex ratio.

Conditions

  • Type2 Diabetes Mellitus

Interventions

DIAGNOSTIC_TEST

Blood sample

Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Tarek Mostafa, Ass Prof. · Tanta University

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-19
Primary Completion
2019-06-30
Completion
2019-07-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04107259 on ClinicalTrials.gov